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Abstract 9 
The clinical distinction between Alzheimer’s disease (AD) and behavioral variant frontotemporal 10 
dementia (bvFTD) remains challenging and largely dependent on the experience of the clinician. This 11 
study investigates whether objective machine-learning algorithms using supportive neuroimaging and 12 
neuropsychological clinical features can aid the distinction between both diseases. 13 
Retrospective neuroimaging and neuropsychological data of 166 participants (54 AD; 55 bvFTD; 57 14 
healthy controls) was analyzed via a Naïve Bayes classification model. A subgroup of patients 15 
(n=22) had pathologically-confirmed diagnoses.  16 
Results show that a combination of grey matter atrophy and neuropsychological features allowed a 17 
correct classification of 61.47% of cases at clinical presentation. More importantly, there was a clear 18 
dissociation between imaging and neuropsychological features, with the latter having the greater 19 
diagnostic accuracy (respectively 51.38% vs. 62.39%). 20 
These findings indicate that, at presentation, machine learning classification of bvFTD and AD is 21 
mostly based on cognitive and not imaging features. This clearly highlights the urgent need to 22 
develop better biomarkers for both diseases, but also emphasizes the value of machine learning in 23 
determining the predictive diagnostic features in neurodegeneration. 24 
1 Introduction 25 
Clinical diagnosis of neurodegenerative diseases at clinical presentation remains challenging, in 26 
particular for phenotypologically similar diseases such Alzheimer’s disease (AD) and behavioral 27 
variant frontotemporal dementia (bvFTD). Diagnostic criteria have been established and revised 28 
(Dubois et al., 2007; Rascovsky et al., 2011) for both diseases, with amnesia seen as a classic 29 
symptom of AD, whereas behavioral changes and executive impairments are reported as core criteria 30 
for bvFTD. However, recent evidence has highlighted that AD patients can present with dysexecutive 31 
and behavioral changes (Possin et al., 2013). Similarly, an important proportion of bvFTD patients, 32 
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including pathologically confirmed patients, have been reported to show similar levels of amnesia as 33 
found in AD (Hornberger & Piguet, 2012; Hornberger, Piguet, Graham, Nestor, & Hodges, 2010; 34 
Bertoux et al., 2014a). 35 
These findings increase the challenge for clinicians in distinguishing between these two diseases at 36 
first presentation. One potential aid to the clinical diagnosis would be the use of machine/statistical 37 
learning algorithms to objectively interpret supportive diagnostic criteria (e.g., neuroimaging, 38 
cognition, etc.) to aid diagnosis based on the core diagnostic features. Such classifiers have been 39 
recently shown to accurately distinguish AD patients from healthy controls (Zhang, Wang, Zhou, 40 
Yuan, & Shen, 2011; Zhou et al., 2014). However, classification against healthy individuals has 41 
limited utility as the distinction of neurodegenerative and healthy individuals is quite straightforward. 42 
More interesting would be to employ machine learning algorithms for the diagnostic distinction of 43 
different neurodegenerative diseases. 44 
The current study addresses this issue by employing a Naïve Bayes classifier model to distinguish 45 
between a large clinical sample of individuals with clinically-diagnosed AD or bvFTD, as well as 46 
automatically separating these two disease classes from healthy age-matched controls at clinical 47 
presentation. Critically, a subset of patients had confirmed pathological diagnoses. Finally, to avoid 48 
circularity, we did not employ in the algorithm any core diagnostic features for the distinction of 49 
patients (such as the Cambridge Behavioural Inventory), as these features were used in the initial 50 
clinical diagnosis and provided the diagnostic reference against which the performance of the 51 
algorithm is compared (except for the pathologically-confirmed cases where pathology provided the 52 
final diagnosis); instead the algorithm utilizes diagnostic supportive features (i.e., atrophy 53 
neuroimaging and neuropsychology) only. Thus, our findings illustrate for the first time how 54 
supportive information can aid clinical diagnosis of these diagnostically challenging similar 55 
neurodegenerative conditions. 56 
2 Methods  57 
2.1 Participants  58 
A total of 166 participants were selected (54 AD; 55 bvFTD; 57 healthy controls) from the 59 
FRONTIER (Frontotemporal Dementia Research Group) patient database, Sydney, Australia. All 60 
bvFTD patients met current consensus criteria (Rascovsky et al., 2011) with insidious onset, decline 61 
in social behavior and personal conduct, emotional blunting, and loss of insight. Patients with a 62 
known genetic mutation associated with bvFTD were not included in the study. All AD patients met 63 
revised NINCDS-ADRDA diagnostic criteria for probable AD (Dubois et al., 2007). Pathological 64 
confirmation of diagnosis was available for 22 patients (9 AD; 13 bvFTD). 65 
Healthy controls were selected from a healthy volunteer panel or were spouses/carers of patients. The 66 
South Eastern Sydney and Illawarra Area Health Service and the University of New South Wales 67 
human ethics committees approved the study. Written informed consent was obtained from the 68 
participant or the primary caregiver in accordance with the Declaration of Helsinki. 69 
 70 
 71 
2.2 Neuropsychological assessment 72 
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All participants underwent cognitive screening using the Addenbrooke’s Cognitive Examination 73 
(ACE-R) (Mioshi, Dawson, Mitchell, Arnold, & Hodges, 2006). The ACE-R results in a score out of 74 
100, and includes subsections in attention, memory, language and visuo-perception. 75 
The frontotemporal dementia rating scale (FRS) (Mioshi, Hsieh, Savage, Hornberger, & Hodges, 76 
2010) was used to determine patients’ disease severity. The Cambridge Behavioural Inventory (CBI) 77 
(Wedderburn et al., 2008) was used as a behavioral disturbance measure. 78 
Patients also underwent a comprehensive cognitive assessment including the Hayling test (Burgess & 79 
Shallice, 1996) that assess inhibition/response suppression, the backward digit span evaluating 80 
working-memory, lexical letter fluency tasks assessing verbal initiation, the Trail Making test 81 
(Reitan, 1955) evaluating flexibility, the recall of the Rey Complex Figure (Rey et al., 1941) as well 82 
as the Doors & People test (Baddeley et al., 1995), two visual memory tests, the Rey Auditory 83 
Verbal Learning Test (RAVLT – Rey et al., 1964) to assess verbal memory and a facial emotion 84 
recognition test based on Ekman faces (Ekman & Friesen, 1975). The cognitive assessments 85 
therefore covered extensive cognitive domains: executive (Digit Span; Hayling; FAS letter fluency; 86 
Trails); memory (Rey Figure Recall; RAVLT recall and recognition; Doors & People) and emotion 87 
recognition (Ekman faces test). Total or subscores of each test were employed in the Bayesian 88 
classification analysis. 89 
2.3 MRI acquisition and analysis 90 
All patients and controls underwent the same imaging protocol to obtain whole-brain T1-weighted 91 
images using a 3T Philips MRI scanner with standard quadrature head coil (8 channels). The 3D T1-92 
weighted sequences were acquired as follows: coronal orientation, 161 mm2 in-plane resolution, slice 93 
thickness 1 mm, TR/TE = 5.8/2.6 ms. MRI analysis was conducted using a Voxel-based 94 
morphometry (VBM) pipeline on three dimensional T1-weighted scans, using the FSL-VBM toolbox 95 
in the FMRIB software library package (http://www.fmrib.ox.ac.uk/fsl/). The first step involved 96 
extracting the brain from all scans using the BET algorithm in the FSL toolbox, using a fractional 97 
intensity threshold of 0.22. Each scan was visually checked after brain extraction, both to ensure that 98 
no brain matter was excluded, and no non-brain matter was included (e.g., skull, optic nerve, dura 99 
mater) (Smith et al., 2004). 100 
A grey matter template, specific to this study, was then built by canvassing 20 scans from each group 101 
(total n = 60). An equal number of scans across groups was used to ensure equal representation, and 102 
thus avoid potential bias toward any single group’s topography during registration. Template scans 103 
were then registered to the Montreal Neurological Institute Standard space (MNI 152) using non-104 
linear b-spline representation of the registration warp field, resulting in study-specific grey matter 105 
template at 2x2x2 mm3 resolution in standard space (Andersson et al., 2007a; Rueckert et al., 1999). 106 
Simultaneously, brain-extracted scans were also processed with the FMRIB’s Automatic 107 
Segmentation Tool (FAST v4.0) to achieve tissue segmentation into cerebrospinal fluid (CSF), grey 108 
matter and white matter. Specifically, this was done via a hidden Markov random field model and an 109 
associated expectation-maximization algorithm (Zhang et al., 2001). 110 
The FAST algorithm also corrected for spatial intensity variations, such as bias field or radio-111 
frequency inhomogeneities in the scans, resulting in partial volume maps of the scans. The following 112 
step saw grey matter partial volume maps then nonlinearly registered to the study-specific template 113 
via non-linear b-spline representation of the registration warp. These maps were then modulated by 114 
dividing by the Jacobian of the warp field, to correct for any contraction/enlargement caused by the 115 
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non-linear component of the transformation (Good et al., 2002). After normalization and modulation, 116 
smoothing the grey matter maps occurred using an isotropic Gaussian kernel (standard deviation = 3 117 
mm; full width half maximum= 8 mm). 118 
Based on the known spread of pathology in bvFTD and AD (Seeley et al., 2008), we a priori selected 119 
a subset of normalized, smoothed brain regions for the Bayesian classification analysis. The brain 120 
region boundaries were established via the cortical and subcortical Harvard-Oxford probabilistic 121 
atlases. The selected regions were the: (1) amygdala; (2) hippocampus; (3) medial temporal lobe; (4) 122 
temporal pole; (5) dorsolateral prefrontal cortex (DLPFC); (6) ventromedial prefrontal cortex 123 
(VMPFC); (7) striatum, and; (8) insula. For the selected regions, grey matter intensities were 124 
extracted and multiplied by the mean of the values in the smoothed registered grey matter to give 125 
total volume for each region and participant. The volumes were then corrected for total intracranial 126 
volume, as well as age and gender. 127 
There is of course the opportunity to segment the brain images into smaller sub-regions, for example, 128 
into their left and right hemisphere sub-regions, but given the limited data set available with which to 129 
learn a pattern recognition model, we risk over-learning during the training phase. Therefore, we 130 
conservatively limit the pool to only eight MRI volumetric features. 131 
2.4 Data preparation 132 
Participants were divided into three classes based on their disease classification (two disease classes, 133 
and one control class) as shown in Table 1. 134 
For each participant, a vector of up to 25 numerical features was available, including the 8 MRI 135 
volumetric features and 17 neuropsychological features. This data was arranged in two data matrices, 136 
denoted as 𝑋𝑠𝑐𝑎𝑛 and  𝑋𝑐𝑜𝑔, respectively. The matrix concatenation of all data was also denoted as 137 
𝑋𝑎𝑙𝑙 = (𝑋𝑠𝑐𝑎𝑛,  𝑋𝑐𝑜𝑔). Each row represents one subject and each column represents one feature 138 
variable. 139 
As a number of neuropsychological cognitive scores were unavailable for several subjects, it is 140 
expected that this led to an underestimation of the discriminating capacity of these cognitive 141 
assessments in differentiating AD and bvFTD. A summary of the extent of this missing data is 142 
provided in supplementary Table 1. 143 
In order to compare the performance of a multivariate classifier model in discriminating the two 144 
disease classes of AD and bvFTD (then in discriminating between the three classes of AD, bvFTD 145 
and controls in a second step) using different combinations of the available features as the input, the 146 
following analyses were performed. 147 
2.5 Naïve Bayes classification 148 
The Naïve Bayes classification method is adopted in this study primarily for its ability to handle 149 
missing features, which occurs for some of the neuropsychological assessments (Liu, Lei, & Wu, 150 
2005; Shi & Liu, 2011). A Naïve Bayes classifier is a simple probabilistic classifier based on the 151 
application of Bayes’ theorem (described mathematically below) with the assumption of probabilistic 152 
independence between every pair of features; in practice this is rarely true, as certain features can be 153 
correlated, but Naïve Bayes classifiers demonstrate remarkably robust performance on features which 154 
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are not strictly independent (H. Zhang, 2004). Given a discrete class label Y and n features, x1 155 
through xn, Bayes’ theorem states the following relationship: 156 
P(Y|x1, … , xn) =  
P(Y)P(x1, … , xn|Y)
P(x1, … , xn)
 157 
where P(Y|x1, … , xn) is the posterior probability of class Y being correct given the observed features 158 
in the vector X = (x1, … , xn). Using the naïve independence assumption that features are independent 159 
of each other, 160 
P(xi|Y, x1, … , xi−1, xi+1, … , xn) = P(xi|Y) 161 
the relationship is simplified to: 162 




P(x1, … , xn)
 163 
P(Y|x1, … , xn)  ∝ P(Y) ∏ P(xi|Y)
n
i=1
  164 






That is, the estimated class label which is output as a decision from the classifier model, denoted as 166 
Ŷ, is that which maximizes the expression P(Y) ∏ P(xi|Y)
n
i=1 . 167 
The Naïve Bayes classifier used two steps to classify data, using the MATLAB Statistics and 168 
Machine Learning Toolbox 2014b (Mathworks, Natick, MA, USA): 169 
 Training step: Using training data, the method estimates the parameters of the probability 170 
distributions of xi for each Y, assuming that the xi are conditionally independent; that is, for 171 
each disease class Y, and each feature variable xi, the probability density P(xi|Y) is 172 
approximated with the available training data. In lay terms, P(xi|Y) is the probability of 173 
observing a value for the variable xi given a particular disease class. The feature xi can be 174 
either discrete or continuous, and either would suggest a different model for the probability 175 
density function, P(xi|Y). Since distributions are assumed independent, during training, 176 
missing instances for a particular feature are not included in the frequency count (for discrete 177 
variables) or distribution estimate (for continuous variables, using a Gaussian smoothing 178 
kernel function). 179 
 Prediction step: For any unseen testing data, the method uses the previously estimated 180 
distributions to compute the value P(Y) ∏ P(xi|Y)
n
i=1 , which is proportional to the posterior 181 
probability, P(Y|x1, … , xn) (as shown above), for each possible class Y; either Y ∈182 
{AD, bvFTD} in the first analysis or Y ∈ {AD, bvFTD, control} in the second. The classifier 183 
then chooses the winning class, Ŷ, as the disease class which maximizes P(Y) ∏ P(xi|Y)
n
i=1 . 184 
During testing, for observations that have some but not all missing features, the algorithm 185 
estimates the class label using only non-missing features. 186 
2.6 Ten-fold cross validation 187 
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Rather than dividing the data evenly into training and testing sets, ten-fold cross-validation was used 188 
to obtain a better estimate of how the model will behave on a general data set by averaging out 189 
variations which were introduced by selecting one training/testing split from the data. The 109 AD 190 
and bvFTD subjects (or 166 subjects when also including controls) were randomly divided into ten 191 
similar sized groups such that the proportion of subjects from each disease class was approximately 192 
equal within each group. For each of the ten cross-validation runs, nine groups were used for training 193 
and the remaining group withheld for testing; this was repeated ten times, such that each of the ten 194 
groups were used as testing data for one of the ten repeats. For any of the ten repeats, given the 195 
training data from the other nine groups, the procedure for training the classifier is outlined above; 196 
however, it may be possible that the removal of some exceptionally noisy or highly correlated 197 
features before training may have improved the performance during the testing phase, therefore the 198 
following feature selection procedure was performed as a pre-processing step during the training 199 
phase of the classifier and not using any of the testing data for that repeat/fold. 200 
2.7 Feature selection 201 
As mentioned above, each training set contained data from nine subject groups. Starting with an 202 
empty candidate feature subset, features were sequentially added to the candidate subset until the 203 
addition of further features did not further improve the classification accuracy; this accuracy was 204 
determined using a second ten-fold cross-validation procedure within this training set in order to 205 
evaluate the potential feature subset under consideration. Figure 1 illustrates the entire process of 206 
classification and feature selection. 207 
2.8 Performance metrics 208 
Classification performance was evaluated using both classification accuracy and Cohen’s kappa 209 
statistic (Cohen, 1968). Approximate confidence intervals for accuracy were also listed; they were 210 
derived using the accuracy as calculated from the confusion matrix (pooling classification results 211 
from all ten cross-validation repeats) and the number of subjects for which a classification result is 212 
obtained, so independence between classification results was not strictly observed (due to test data 213 
also being used as training data for other folds) as required when estimating confidence intervals. 214 
Confidence intervals were computed with the approximation that all results were drawn from a fixed 215 
classifier model (rather than cross-validation, which is actually used). 216 
2.9 Evaluating three different feature sets 217 
In order to compare the usefulness of the MRI scans volumes and the neuropsychological assessment 218 
(cognitive and neuropsychiatric) features three different starting feature sets (before feature selection 219 
begins), 𝑋𝑠𝑐𝑎𝑛,  𝑋𝑐𝑜𝑔, and 𝑋𝑎𝑙𝑙 were evaluated using the procedure shown in Figure 1. 220 
3 Results 221 
3.1 Classifying AD and bvFTD  222 
Table 2 shows the classification results in discriminating AD and bvFTD (without considering the 223 
control group). Using the MRI volume features as input, the machine learning algorithm classified 224 
51.4% (50% when considering only 22 confirmed cases) of bvFTD and AD patients correctly at 225 
presentation. In contrast, the neuropsychological scores achieved higher discrimination accuracy, 226 
correctly identifying 62.4% of bvFTD and AD cases. Not surprisingly, due to the low classification 227 
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accuracy when using MRI volumes, the combined feature set (MRI volumes and neuropsychological) 228 
was only slightly decreased to 61.5% of correct discrimination between bvFTD and AD. 229 
Figure 2 shows a histogram of the ten sets of features selected for each of the ten outer cross-230 
validation runs, for a given starting feature set (derived from either the MRI volumes, 231 
neuropsychological assessment, or both combined). The higher the frequency with which the feature 232 
is selected, the more consistently it contributes to the classification task. There was a large variability 233 
across features contributing to successful discrimination. Using only MRI scan volume features 234 
(shown as white bars in Figure 2), six of the eight MRI regions were selected at least once, except for 235 
the striatum (which is never selected when discriminating between AD and bvFTD, and so not shown 236 
in Figure 2) and the hippocampus. The most selected regions were the temporal pole, insula, and 237 
temporal lobe. For the neuropsychological features (shown as grey bars in Figure 2), 7 of the 17 were 238 
selected at least once, with ACE-R memory subtest, Hayling AB errors, Doors & People test, and 239 
facial emotion recognition of fear scores being selected more than twice, and with the ACE-R 240 
memory subscore and Hayling AB errors being selected more than twice as often as the next most 241 
frequently selected neuropsychological feature (Doors & People test scores).  242 
3.2 Classifying AD, bvFTD and controls 243 
Table 3 shows the classification results in discriminating AD, bvFTD and control classes. MRI 244 
features achieved an accuracy of 54.2% (18.2%, when considering the 22 confirmed cases only). As 245 
in the previous classification, the three-class classification performed better using neuropsychological 246 
features, with an accuracy of 68.1%. The combination of both MRI and neuropsychological features 247 
achieves an accuracy of 67.5% (although confidence intervals overlap almost entirely). 248 
The corresponding feature selection results are shown in Figure 3. The most selected features when 249 
using only MRI features were the DLPFC, temporal lobe, VMPFC and temporal pole. When using 250 
neuropsychological features, the most commonly selected features were ACE-R memory and ACE-R 251 
fluency subscores as well as facial emotion recognition of fear. Combining all (neuropsychological 252 
and imaging) features in the analysis, these same three neuropsychological features remained among 253 
the most selected, however, DLPFC and temporal lobe (which were the two most frequently selected 254 
features when using only MRI scan features) are each only selected for one of the ten cross-255 
validation runs. This last result indicates that the neuropsychological features already contained this 256 
same scan information. Interestingly, when combining both scan and neuropsychological features, 257 
the striatum is selected twice as often (rising from being selected twice to being selected four times). 258 
4 Discussion 259 
To our knowledge, this is the first study investigating the use of machine learning algorithms to 260 
differentiate AD and specifically bvFTD. Results showed that neuropsychological scores and 261 
particularly tests of emotion recognition, memory screening and executive assessment achieved the 262 
best classification results. Cortical volumes of a subset of frontal, temporal and insular regions were 263 
the most distinctive anatomical features to distinguish the groups. 264 
Previous neurodegenerative machine learning studies have virtually been all focused on AD and its 265 
prodromal stages (Cuingnet et al., 2011; Hinrichs, Singh, Xu, & Johnson, 2011; Walhovd et al., 266 
2010; D. Zhang et al., 2011; Zhou et al., 2014), whereas only one study examined discriminating AD 267 
from more general frontotemporal lobar degeneration (FTLD) (Klöppel et al., 2008) as a clinical 268 
spectrum. In addition, virtually all these studies have focused mostly on neuroimaging features, and 269 
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none have attempted to distinguish between the specific diseases of AD and bvFTD, whereas the 270 
current study used additional neuropsychological features as well as a pathologically confirmed 271 
bvFTD patient subgroup. 272 
On a cognitive level, the most salient neuropsychological features to accurately classify AD and 273 
bvFTD were assessment of emotion recognition (Ekman faces), inhibition (Hayling), visual episodic 274 
memory (Doors & People) and verbal memory screening (ACE-R memory). These findings nicely 275 
corroborate previous results showing that, at presentation, emotion recognition deficits and 276 
disinhibition are hallmarks of bvFTD while being relatively absent in AD (Hornberger et al., 2011; 277 
Bertoux et al., 2014b). In contrast, AD patients’ prevalent episodic memory problems were most 278 
distinctive for this patient group, although some bvFTD can show impaired episodic memory 279 
performance (Hornberger et al., 2010; Bertoux et al., 2014a). More specifically, a subgroup of 280 
bvFTD patients can show severe episodic memory problems, which limits the utility of episodic 281 
memory problems in the diagnostic distinction of both diseases. Future machine learning approaches 282 
on such amnestic bvFTD compared to AD patients would be of importance to confirm this notion. 283 
Finally, the similar neuropsychological factors were found to discriminate groups when controls were 284 
also added in the analysis, further corroborating the robustness of the findings. 285 
On an anatomical level, the temporal pole and insula were the most distinctive features to distinguish 286 
between AD and bvFTD. The insula has been previously shown to be among the earliest of the 287 
regions atrophic in bvFTD (Perry et al., 2006) and is selectively impaired compared to AD. The 288 
identification of the temporal lobe as a significant feature to distinguish both diseases is an intriguing 289 
result, as both AD and bvFTD show significant changes in this region. Nevertheless, the atrophy of 290 
the temporal pole, which accounts for a large part of the temporal lobe, might explain this finding, as 291 
it is indeed strongly associated with bvFTD pathology (Whitwell et al., 2009). The atrophy findings 292 
are therefore strongly dominated by the bvFTD atrophy pattern spanning temporal pole and insular 293 
regions, whereas interestingly prefrontal cortex regions (DLPFC, VMPFC) as well as medial 294 
temporal lobe regions contributed little to the classification accuracy. This is further confirmed by the 295 
analysis including the controls, which only then showed volumes of the VMPFC and DLPFC as well 296 
as of the temporal lobe and pole strongly contributing to the classification. 297 
Interestingly, neuropsychological features outperformed cortical volume features for the 298 
classification accuracy between bvFTD and AD (62.4% versus 51.4%, for cortical volume or 299 
neurophysiological features, respectively). More intriguing is the fact that the combination of atrophy 300 
and neuropsychological features did not increase the classification accuracy. This indicates a 301 
redundancy in the variables with neuroimaging and cognitive features seemingly representing the 302 
same dysfunction. Finally, similar classification results were observed when the analysis was 303 
restricted to the pathologically confirmed cases for which the neuropsychological measures showed a 304 
classification rate of 54.6% and atrophy features an even a lower accuracy rate of 50.0%. It is likely 305 
that the difference in sample size between the overall group (n=109) and the pathological confirmed 306 
cases (n=22) may explain the difference of classification accuracy for the combining features 307 
between the analyses (62.4% for n=109, and 54.6% for n=22). Still, it is important to note that 308 
classification results were relatively similar in the pathological subgroup as it still represents the gold 309 
standard of definite diagnosis in both diseases. 310 
It is interesting to note that the previous study by Klöppel et al. (2008) achieved much higher 311 
sensitivity and specificity (94.7% and 83.3%, respectively) using MRI atrophy contrasts of AD and 312 
FTLD, showing that parietal and frontal changes were particularly informative in the distinction of 313 
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AD and FTLD, respectively. However, the inclusion of language-variant FTLD together with 314 
behavioral-variant, as well as the exclusion of bvFTD patients with memory impairment could 315 
explain the difference with our results, as it has been shown that AD and bvFTD can overlap to a 316 
large degree for scan-based measures (Hornberger & Piguet, 2012; Hornberger et al., 2012; de Souza 317 
et al., 2013), whereas other FTLD clinical subtypes (sv-FTD; nfv-PPA) show more distinct scan 318 
features (Gorno-Tempini et al., 2011). Also, a key differences between Klöppel et al.’s study and 319 
ours is that we used more specific regions (e.g., VMPFC) as neuroimaging features instead of the 320 
entire cortical lobes (e.g., frontal lobe), which may have lowered the general discriminative power. 321 
Another novelty in our study was the employment of a three-way classification (AD, bvFTD, and 322 
controls) in a post-hoc analysis, which allowed contrasting the patient groups with controls at the 323 
same time. While it is not possible to directly compare these results with other reports in the 324 
literature, an approximate comparison can be made against several reported attempts to distinguish 325 
AD from controls. Previous studies showed good sensitivity/specificity (>80% sensitivity and >90% 326 
specificity) of imaging measures to distinguish AD from controls (Hamelin et al., 2015). In our 327 
results (Table 3), using the neuroimaging features resulted in 8 normal controls being erroneously 328 
classified as AD patients, and 28 diseased patients (18 AD and 10 bvFTD) wrongly classified as 329 
normal. In contrast, using neuropsychological scores instead in the model resulted in much fewer 330 
errors when classifying between controls and patients. Interestingly, these results are similar to 331 
Hinrichs et al. (2011) which reported that both cognitive and neuroimaging features contributed to 332 
the prediction of MCI patients progressing to full-blown AD – with neuroimaging features 333 
contributing slightly more to the classification. As mentioned already above, it is currently not clear 334 
how much cognitive and neuroimaging atrophy features map onto each other, however, it becomes 335 
apparent that even if there is some redundancy, a complementary diagnostic and classification 336 
approach can potentially corroborate diagnosis based on only one feature. There is clearly great scope 337 
to explore this further in the future, in particular in the distinction of neurodegenerative conditions 338 
from each other. 339 
Despite these promising results there are limitations to our findings. In particular, only a subset of 340 
patients had a pathologically confirmed diagnosis. Ideally, we would have pathological confirmation 341 
in all patients. Still, the pathological confirmed participants showed similar results to the clinical 342 
cohort. A further limitation might have been the selection of specific neuroimaging and cognitive 343 
features in the analysis. As outlined in the methods, the a priori reasoning was to include features 344 
that have been shown to be most sensitive and specific to the respective pathologies. However, this 345 
might mean that other features which potentially could have allowed better classification were not 346 
considered in the current analysis. There may also be a small positive bias in the results due to the 347 
registration of brain images prior to the machine-learning exercise performed herein (that is, images 348 
are normalized using all available data outside of the cross-validation loop); however, failing to 349 
perform such registration would likely lead to a larger negative bias in results due to the effects of 350 
age and gender covariates which also correlate with tissue volumes. Missing data among the 351 
neuropsychological assessment features will also have resulted in a lesser reported accuracy than 352 
what is achievable if these data were complete; hence, neuropsychological assessment could 353 
outperform MRI scans in this diagnostic task by a greater margin than what is presented herein. 354 
Finally, despite the sample size being excellent for clinical studies, the current sample size poses a 355 
challenge for modelling techniques, such as the one used here. In particular, the sample size relative 356 
to number of features can lead to worse performance than true performance in wild due to overfitting 357 
during feature selection and training; i.e., large variation in features selected between cross-validation 358 
runs. It would be therefore important to replicate our results in independent and larger samples in the 359 
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future. Still, we believe that the current findings are of importance and highlight how, in the near 360 
future, clinicians could use novel computational techniques at a single patient level to aid their 361 
clinical diagnoses. 362 
Taken together, this study used a machine-learning classifier to distinguish AD and bvFTD. Despite 363 
showing promising findings, the separability of the three groups, and in particular between the two 364 
patient groups, was lower than expected. Cortical volume in temporo-insular regions allowed a 365 
classification accuracy of 51.4% between AD and bvFTD, while neuropsychological scores of 366 
emotion recognition, cognitive inhibition and memory reached approximately 62.4% accuracy. These 367 
results suggest that machine-learning classifier for AD and bvFTD should rely more on cognitive 368 
performance than cortical volumes and can provide clinicians with objective supportive information 369 
under diagnostic uncertainty. 370 
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6 Tables  481 
Table 1: Three classes of data, which include two disease classes, Alzheimer’s disease (AD) and 482 
behavioral variant frontotemporal dementia (bvFTD), and a control group. Age, years of education, 483 
and disease duration are tested for group differences using Kruskal-Wallis tests. Gender is tested for 484 
group differences using Chi-squared test. Only education is shown not to be different between groups 485 
at 5% level of significance. 486 
 AD 
(n = 54) 
bvFTD 
(n = 55) 
Controls 
(n = 57) 
p-values 
Age (years) 63.7 (8.1) 61.2 (9.4) 67.3 (6.8) 0.001 
Gender (M/F) 31/23 37/18 25/32 0.043 
Education (years) 12.3 (3.7) 12.3 (3.3) 13.1 (2.8) 0.138 
Disease duration (years) 3.3 (2.1) 4.7 (3.3) - 0.041 
 487 
Table 2: Results for classification of AD versus bvFTD (n=109). Each column of a confusion matrix 488 
represents the true class label, while each row represents the estimated class label. Within confusion 489 
matrices, the first columns/rows represent AD, while the second columns/rows represent bvFTD. The 490 
mean and standard deviation (SD) of each confusion matrix entry across the ten cross-validation runs 491 
are also presented. Cohen’s kappa coefficient and accuracy are calculated for the confusion matrix. 492 
The corresponding confirmed diagnoses are shown in parentheses. Approximate 95% confidence 493 
intervals (CI) are provided for classification accuracies.  494 
  Starting feature subset before feature selection 
  









































3.6 ± 1.17 3.5 ± 1.27
1.8 ± 1.03 2.0 ± 0.94
 
3.4 ± 1.08 2.1 ± 1.10
2.0 ± 1.49 3.4 ± 1.07
 
3.2 ± 0.92 2.0 ± 1.15
2.2 ± 1.14 3.5 ± 1.18
 
Cohen’s kappa 
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Table 3: Results for classification of AD, bvFTD, and control (n=166). Each column of a confusion 497 
matrix contains the actual disease diagnosis, while the rows contain the disease class estimated by the 498 
classifier. The first, second, and third columns/rows represent AD, bvFTD, and control, respectively. 499 
Corresponding results for confirmed diagnoses are shown in parentheses. Approximate 95% 500 
confidence intervals (CI) are provided for classification accuracies. 501 


















































2.2 ± 1.23 2.6 ± 1.26 0.8 ± 0.63
1.4 ± 1.26 1.9 ± 1.29 0.0 ± 0.00
1.8 ± 1.14 1.0 ± 0.82 4.9 ± 0.88
 
2.9 ± 1.37 1.5 ± 1.08 0.0 ± 0.00
2.2 ± 1.75 3.1 ± 1.20 0.4 ± 0.70
0.3 ± 0.95 0.9 ± 0.88 5.3 ± 0.82
 
2.9 ± 0.99 1.7 ± 1.16 0.0 ± 0.00
1.9 ± 1.29 2.8 ± 0.92 0.2 ± 0.63






























7 Figure Legends 503 
Figure 1: Block diagram of training and testing of Naïve Bayes classification model. One outer 504 
loop performs the testing, using ten different groups with approximately 16 or 17 subjects in each 505 
group when n=166 for three-way classification of AD, bvFTD, and control. The nine groups used for 506 
training in each run are subject to further feature selection to remove redundant or noisy features; 507 
each candidate feature subset is evaluated using an inner 10-fold cross-validation procedure. 508 
Figure 2: Accumulated feature selection results of ten-fold cross validation in discriminating 509 
AD and bvFTD using three different feature sets: MRI volumes (*Scan), neuropsychological 510 
(Cognitive) and both combined. Y-axis shows the name of selected features and X-axis shows the 511 
accumulated count of a corresponding feature being selected over the ten folds. Three sets of features 512 
are displayed in different colors. 513 
Figure 3: Accumulated feature selection results of ten-fold cross validation in discriminating 514 
AD, bvFTD and control classes using three different feature sets: MRI volumes (*Scan), 515 
neuropsychological (Cognitive) and both combined. Y-axis shows the name of selected features 516 
and X-axis shows the accumulated count of a corresponding feature being selected over the ten folds. 517 
Three sets of features are displayed in different colors. 518 
